Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NTRK1 | P04629 | 3/20 | 0.43 |
| ▸ | CCNA2 | P20248 | 5/20 | 0.41 |
| ▸ | CDK2 | P24941 | 5/20 | 0.41 |
| ▸ | CDK9 | P50750 | 4/20 | 0.41 |
| ▸ | CCNK | O75909 | 3/20 | 0.41 |
| ▸ | CCND3 | P30281 | 2/20 | 0.41 |
| ▸ | CDK6 | Q00534 | 2/20 | 0.41 |
| ▸ | PTK2 | Q05397 | 4/20 | 0.41 |
| ▸ | ALK | Q9UM73 | 3/20 | 0.40 |
| ▸ | AXL | P30530 | 3/20 | 0.39 |
| ▸ | STK17A | Q9UEE5 | 3/20 | 0.39 |
| ▸ | STK17B | O94768 | 2/20 | 0.39 |
| ▸ | MET | P08581 | 2/20 | 0.38 |
| ▸ | BTK | Q06187 | 2/20 | 0.38 |
| ▸ | MAPK3 | P27361 | 1/20 | 0.38 |
| ▸ | CDC7 | O00311 | 1/20 | 0.38 |
| ▸ | PLK4 | O00444 | 1/20 | 0.38 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.38 |
| ▸ | AURKA | O14965 | 1/20 | 0.38 |
| ▸ | DCLK1 | O15075 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2468711 | 0.90 | NTRK1 (0.55) | NTRK1CCNA2CDK2CDK9CCNK | |
| SCHEMBL2473723 | 0.89 | NTRK1 (0.41) | NTRK1CCNA2CDK2CDK9CCNK | |
| SCHEMBL1606776 | 0.88 | PTK2 (0.42) | NTRK1CCNA2CDK2CDK9CCNK | |
| SCHEMBL1607130 | 0.88 | ALK (0.47) | NTRK1CCNA2CDK2CDK9CCNK | |
| SCHEMBL2470400 | 0.87 | NTRK1 (0.59) | NTRK1CCNA2CDK2CDK9CCND3 | |
| SCHEMBL1606740 | 0.81 | CCNK (0.63) | NTRK1CCNA2CDK2CDK9CCNK | |
| SCHEMBL1606946 | 0.81 | BRD4 (0.54) | CCNA2CDK2CDK9CCNKCCND3 | |
| SCHEMBL2475717 | 0.80 | BRD4 (0.46) | NTRK1CCNA2CDK2PTK2ALK | |
| SCHEMBL2474071 | 0.79 | NTRK1 (0.53) | NTRK1CCNA2CDK2CDK9PTK2 | |
| SCHEMBL1607687 | 0.78 | PTK2 (0.41) | NTRK1CCNA2CDK2CDK9CCNK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2370415-B1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | RIGEL PHARMACEUTICALS INC (US) | 2016-04-20 | — | — | EP | claimed |
| US-8268851-B2 | Compositions and methods for inhibition of the JAK pathway | RIGEL PHARMACEUTICALS, INC. (US) | 2012-09-18 | — | — | US | claimed |
| EP-2370415-A2 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | Rigel Pharmaceuticals, Inc. (US) | 2011-10-05 | — | — | EP | claimed |
| WO-2010075558-A2 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | RIGEL PHARMACEUTICALS, INC. (US) | 2010-07-01 | — | — | WO | claimed |
| US-20100158921-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | RIGEL PHARMACEUTICALS, INC. (US) | 2010-06-24 | — | — | US | claimed |
| EP-2370415-B1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | RIGEL PHARMACEUTICALS INC (US) | 2016-04-20 | — | — | EP | disclosed |
| US-8268851-B2 | Compositions and methods for inhibition of the JAK pathway | RIGEL PHARMACEUTICALS, INC. (US) | 2012-09-18 | — | — | US | disclosed |
| US-20100158921-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | RIGEL PHARMACEUTICALS, INC. (US) | 2010-06-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100158921-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | JAK3, JAK2, JAK1 | NTRK1 4361/4885CCNA2 1836/4885CDK2 236/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.